Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tibor Wenger is active.

Publication


Featured researches published by Tibor Wenger.


Peptides | 2000

Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study

Gabriella Moldrich; Tibor Wenger

The presence of central cannabinoid receptor (CB1), involving the N-terminal 14 amino acid peptide, was demonstrated in the rat brain by immunohistochemistry. Intensely stained neurons were observed in the principal neurons of the hippocampus, striatum, substantia nigra, cerebellar cortex, including the Purkinje cells. Moderate CB1-IR cell bodies and fibers were present in the olfactory bulb, cingulate, entorhinal and piriform cortical areas, amygdala and nucleus accumbens. The perivascular glial fibers have shown moderate to high density CB1-IR in olfactory and limbic structures. Low density was detected in the thalamus and hypothalamus and area postrema. The CB1 receptor was widely distributed in the forebrain and sparsely in the hindbrain. These new data support the view that the endogenous cannabinoids play an important role in different neuronal functions as neuromodulators or neurotransmitters.


Neuroendocrinology | 1999

IDENTIFICATION OF ENDOCANNABINOIDS AND CANNABINOID CB1 RECEPTOR MRNA IN THE PITUITARY GLAND

Sara González; Jorge Manzanares; Fernando Berrendero; Tibor Wenger; Javier Corchero; Tiziana Bisogno; J. Romero; José A. Fuentes; V. Di Marzo; J.A. Ramos; J.J. Fernández-Ruiz

Most data on effects of natural and synthetic cannabinoids on anterior pituitary hormone secretion point out to a primary impact on the hypothalamus. There is also some evidence, however, of possible direct actions of these compounds on the anterior pituitary, although the presence of cannabinoid receptors in the pituitary has not been documented as yet. In the present study, we evaluated the presence of cannabinoid CB1 receptor-mRNA transcripts in the pituitary gland by in situ hybridization. We observed CB1 receptor-mRNA transcripts in the anterior pituitary and to a lesser extent in the intermediate lobe whereas they were absent in the neural lobe. We then examined whether CB1 receptor-mRNA levels in both pituitary lobes responded to chronic activation by a specific agonist, as did receptors located in adjacent hypothalamic nuclei and in other brain regions. Daily administration of CP-55,940 for 18 days produced a small, but statistically significant paradoxical increase in CB1 receptor-mRNA levels in the anterior pituitary, with no changes in the intermediate lobe, in contrast to reduced CB1 receptor-mRNA levels observed in the ventromedial hypothalamic nucleus (VMN), and to decreased CB1 receptor binding in the VMN and the arcuate nucleus. The time-course of up-regulation of CB1 receptor-mRNA transcripts in the anterior lobe was biphasic; daily administration of Δ9-tetrahydrocannabinol produced an early and marked decrease in CB1 receptor-mRNA levels after 1 and 3 days, followed by normalization after 7 days and by a small increase after 14 days. We also checked whether endogenous cannabinoid ligands are present in the anterior pituitary and the hypothalamus. Although anandamide itself was detected only in trace amounts, concentrations of its precursor N-arachidonoyl-phosphatidyl-ethanolamine and of 2-arachidonoyl-glycerol were found in both tissues, suggesting that endocannabinoids may be synthetized in the anterior pituitary. In summary, CB1 receptors and corresponding ligands seem to be expressed in cells of the anterior and intermediate lobes of the pituitary, but the response of CB1 receptor-mRNA transcripts in the anterior lobe to chronic agonist activation is different than the desensitization observed in hypothalamic nuclei.


Brain Research Bulletin | 2003

Neuromorphological background of cannabis addiction

Tibor Wenger; Gabriella Moldrich

The expression of central cannabinoid (CB1) receptors in tyrosine hydroxylase (TH) containing neurones was demonstrated. Co-localisation was present in different brain areas responsible for reward-related mechanisms. The immunohistochemical investigations have shown that co-localisation is present in parts of mesolimbic-mesocortical dopaminergic system like nucleus accumbens (Nacb), ventral tegmental area (VTA), in the striatum, pyriform cortex, respectively. The results suggest a functional role of CB1 receptors in cannabis addiction by acting directly on reward-related structures.


Neuroendocrinology | 1987

Effects of delta-9-tetrahydrocannabinol on the hypothalamic-pituitary control of luteinizing hormone and follicle-stimulating hormone secretion in adult male rats.

Tibor Wenger; Valeria Rettori; G D Snyder; S. Dalterio; Samuel M. McCann

The main psychoactive component of marihuana, delta-9-tetrahydrocannabinol (THC) was injected into the 3rd cerebral ventricle. A single dose of THC (2 microliter of 10(-6) M) decreased serum LH temporarily but did not alter serum follicle-stimulating hormone (FSH) levels. The mediobasal hypothalamic (MBH) luteinizing hormone-releasing hormone (LHRH) content was elevated by 30 min after the injection. The elevation persisted for 1 h. Then, the LHRH content returned towards the preinjection level. In contrast, the LHRH in the organum vasculosum of the lamina terminalis did not change after a single dose of THC. The results indicate that THC alters pituitary LH release by inhibiting the release of LHRH which then increases in the MBH by continued synthesis or transport from rostral areas. In addition, the data support the existence of an FSH releasing factor, the release of which is not suppressed by this dose of THC. THC did not alter the release, storage or responsiveness to LHRH of cultured anterior pituitary cells, which further supports the view that its principal site of action is on the hypothalamus.


Life Sciences | 2002

The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats

Tibor Wenger; Ida Gerendai; Filomena Fezza; Sara González; Tiziana Bisogno; Javier Fernández-Ruiz; Vincenzo Di Marzo

Several data suggest that the endogenous cannabinoid system plays a role in neuroendocrine regulation in adult individuals, although the information on its involvement in peri-pubertal processes is scarce. In the present study, we have examined the ontogeny (from postnatal day [PND] 5 up to adulthood) of hypothalamic and anterior pituitary contents of anandamide (arachidonyl-ethanolamide, AEA). We observed that the content of AEA in the hypothalamus was low at PND5, PND15 and PND25, but it markedly increased (approximately 3-fold) immediately before the puberty (on the day of 1st proestrus), to return to intermediate values immediately after the vaginal opening (day of 2nd proestrus) and, eventually, adulthood. By contrast, no consistent differences were observed in AEA levels in the anterior pituitary. These results demonstrate the occurrence of a parallelism between the peri-pubertal events and a rise in the hypothalamic content of AEA immediately before the puberty, which might indicate that this endocannabinoid may be involved in the onset of puberty in rats.


Neuroendocrinology | 1988

Hypothalamic Action of Delta-9-Tetrahydrocannabinol to Inhibit the Release of Prolactin and Growth Hormone in the Rat

Valeria Rettori; Tibor Wenger; G D Snyder; Susan Dalterio; Samuel M. McCann

The site of action of delta-9-tetrahydrocannabinol (THC) to inhibit the release of prolactin (PRL) and growth hormone (GH) was examined by in vivo and in vitro experiments. In conscious freely moving animals bearing implanted third ventricular (3V) and external jugular cannulae, THC or the diluent was microinjected into the 3V and blood samples were removed to determine the effect on plasma PRL and GH. Both the 0.4- and 4-micrograms dose injected intraventricularly resulted in a suppression of PRL and GH release as indicated by declines in plasma levels within 40-80 min which were highly significant statistically but not dose-related. The higher dose evoked a pulse of GH and/or PRL in most animals which preceded the lowering of hormonal levels. In the in vitro experiments dipersed anterior pituitary cells were incubated with 5 x 10(-8) or 5 x 10(-9)M THC or the diluent for 5 days. Fresh culture medium was added to the cells after 3 days and the cells cultured for an additional 2 days. After this period, the cells were incubated for an additional 2 h in culture medium with or without THC plus a near maximal dose of thyrotropin-releasing hormone and GH-releasing factor (50 and 10 ng/ml, respectively) or the diluent to evaluate the response of PRL and GH release, respectively. Neither dose of THC altered the release or storage of the two hormones during culture or affected the response to the releasing hormones which is suggestive that there is no direct effect of THC on either GH or PRL release.(ABSTRACT TRUNCATED AT 250 WORDS)


Neuroendocrinology | 2003

The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice.

Tibor Wenger; Catherine Ledent; G. Tramu

The purpose of this study was to investigate the effects of the endogenous cannabinoid arachidonoyl-ethanolamide, anandamide (AEA), on the activity of the hypothalamo-pituitary-adrenal (HPA) axis in cannabinoid receptor (CB1 receptor) inactivated (KO) mice. A low dose (0.01 mg/kg i.p.) of AEA significantly increased plasma corticotropin (ACTH) and corticosterone concentrations in both wild-type (+/+) and in mutant (–/–) animals. In each case, hormone levels reached their peaks at 90 min after AEA administration. In a parallel experiment, AEA administration was preceded by the injection of SR 141716A (1.0 mg/kg), a selective and potent CB1 receptor antagonist, or of capsazepine (5.0 mg/kg), a potent vanilloid receptor of type 1 (VR1) antagonist. The latter drugs did not prevent the effects of AEA on the HPA axis. Using Fos protein immunohistochemistry, we observed that the parvocellular part of the hypothalamic paraventricular nucleus (PVN) was activated as early as 45 min after AEA injection and reached peak levels after 60 min in both +/+ and –/– mice. Furthermore, the CB1 and VR1 receptor antagonists did not block the effects of AEA on Fos immunoreactivity. The results strongly support the view that activation of the HPA axis produced by AEA possibly occurs via a currently unknown (CBx) cannabinoid receptor present in PVN.


Life Sciences | 1999

The effects of cannabinoids on the regulation of reproduction

Tibor Wenger; Béla Tóth; Christian Juaneda; Jean Leonardelli; G. Tramu

It has been shown that the main psychoactive component of marihuana, delta9-tetrahydrocannabinol (THC) has mainly inhibitory effects on the regulation of reproduction. Recently, the purification and availability of the endogenous ligand of the cannabinoid receptor, arachidonyl ethanolamide, anandamide, (ANA) and its specific long lasting antagonist, the SR 141716 (SR) provided us the opportunity to compare the effects of THC and ANA on the neuroendocrine regulation of reproduction. ANA decreases serum luteinizing hormone (LH) and prolactin (PRL) levels in rats of both sexes. It has no action on serum follicle stimulating hormone (FSH) level. When ANA was administered to pregnant rats it resulted in an increase of the duration of pregnancy and in the frequency of stillbirths. The postnatal development of hypothalamo-pituitary axis in offspring was temporarily inhibited. In conclusion, we found that exogenous and endogenous cannabinoids have only slightly different effects on the reproductive parameters. These effects may occur via the central cannabinoid receptor. It is possible that the sites of action are at both hypothalamic and pituitary levels. The results further support the view that ANA may be a central neurotransmitter or neuromodulator.


Acta Histochemica | 1980

Immunohistochemical localization of substance P and ACTH-like activity in the central nervous system of the earthworm Lumbricus terrestris L.

Béla Aros; Tibor Wenger; B. Vigh; I. Vigh-Teichmann

The peroxidase-antiperoxidase (PAP) method was used for the immunohistological demonstration of substances P and ACTH in the cerebral and subesophageal ganglia of the earthworm, Lumbricus terrestris L. With rabbit antibody to substance P a positive immunoreaction was found in nerve cells smaller than the type A neurons of the cerebral ganglion. Their perikarya and nerve processes as well as their terminal enlargements in the synaptic zone were immunoreactive. ACTH-like activity was visible in a larger perikaryon type of the A neurons. Their nerve processes did not show any reaction. However, a part of the nerve terminals of the synaptic zone and a few neurons of type B of the cerebral ganglion, further some cells of the subesophageal ganglion reacted positively.


Neurochemistry International | 2008

Noladin ether, a putative endocannabinoid, inhibits μ-opioid receptor activation via CB2 cannabinoid receptors

Estera Páldyová; Erika Bereczki; Miklós Sántha; Tibor Wenger; Anna Borsodi; Sándor Benyhe

We examined the occurrence of possible changes in mRNA expression and the functional activity of opioid receptors after acute in vivo and in vitro treatment with the putative endogenous cannabinoid noladin ether. While noladin ether (NE) demonstrates agonist activity at CB1 cannabinoid receptors, recent data indicate that NE acts as a full agonist at CB2 cannabinoid receptors too. Considering the functional interactions between opioids and cannabinoids, it is of interest to examine whether NE affects the opioid system. To that end, we studied the influence of NE on mu-opioid receptor (MOR) mRNA expression and MOR mediated G-protein signaling. We used real-time PCR and [35S]GTPgammaS binding assays to examine the changes of MOR mRNA levels and the capability of the mu-opioid agonist peptide ([D-Ala2,(NMe)Phe4,Gly5-ol]enkephalin (DAMGO) in activating regulatory G-proteins via MORs in forebrain membrane fractions of wild-type (w.t., CB1+/+) and CB1 receptor deficient transgenic mice (knockout, CB1-/-). We found, that the expression of MOR mRNAs significantly decreased both in CB1+/+ and CB1-/- forebrain after a single injection of NE at 1 mg/kg when compared to control. Consequently, MOR-mediated signaling is attenuated after acute in vivo treatment with NE in both CB1+/+ and CB1-/- mice. Inhibition on MOR mediated activation is observed after in vitro NE administration as well. Radioligand binding competition studies showed that the noticed effect of NE on MOR signaling is not mediated through MORs. Both in vivo and in vitro attenuations of NE can be antagonized by the CB2 selective antagonist SR144528. Taken together, our data suggest that the NE caused pronounced decrease in the activity of MOR is mediated via CB2 cannabinoid receptors.

Collaboration


Dive into the Tibor Wenger's collaboration.

Top Co-Authors

Avatar

G. Tramu

Semmelweis University

View shared research outputs
Top Co-Authors

Avatar

Anna Borsodi

Hungarian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

B. Vigh

Semmelweis University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G. Tramu

Semmelweis University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Miklós Sántha

Hungarian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sándor Benyhe

Hungarian Academy of Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge